Outcomes of treatment for Stage III endometrial carcinoma patients

Purposes: To report the outcomes and patterns of failure of Stage III endometrial carcinoma. Materials and Methods: Medical records of Stage III endometrial carcinoma patients were retrospectively reviewed. Disease-free survival (DFS) and patterns of failure were reported. Factors to predict pelvic and extra-pelvic recurrences were described. Results: Seventy-nine patients with Stage III endometrial carcinoma were included. Most had Stage IIIA (53%) and IIIC disease (33%) with endometrioid cell types (73%). Fifty-five percent of patients received chemotherapy (CMT) alone, 25% received external beam radiation therapy (ERT) alone, 20% received a combination of CMT and ERT. Median follow up time was 47 months. The two-year DFS rate was 78.5%. Pelvic and extra-pelvic recurrences were found in 6.3% and 15.2%, respectively. Major pattern of failure for Stage IIIA was pelvic recurrences, whereas most of Stage IIIC disease failed at the extra-pelvic sites. Conclusion: Adjuvant CMT is essential, especially in Stage IIIC disease. Pelvic lymph node dissection appeared to be a significant prognostic factor for pelvic recurrence. Stage IIIC disease, lymphovascular space invasion, gross residual disease after surgery, received ERT alone or sequential CMT/ERT was found to be factor to predict extra-pelvic recurrences.

Endometrial carcinoma; Stage III; Outcome; Pattern of failure

[1] Siegel R.L., Miller K.D., Jemal A.: “Cancer Statistics, 2017”. CA. Cancer J. Clin., 2017, 67, 7.

[2] Chinswangwatanakul V.: “Siriraj Cancer Registry 2015”. Siriraj Cancer Registry, 2015, 9.

[3] Koh W.J., Greer, B.E., Abu-Rustum, N.R., Bean S., Bradley K., Campos S.M., et al.: “National Comprehensive Cancer Network. Uterine neoplasm (version 1.2018)”. Available at: http://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

[4] Siegel R., Ward E., Brawley O., Jemal A.: “Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths”. CA. Cancer J. Clin., 2011, 61, 212.

[5] Morice P., Leary A., Creutzberg C., Abu-Rustum N., Darai E.: “Endometrial cancer”. Lancet., 2016, 387, 1094.

[5] Klopp A.H., Smith B.D., Alektiar K., Cabrera A., Damato A.L., Erickson B., et al.: “The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline”. Pract. Radiat. Oncol., 2014, 4, 137.

[7] Nout R.A., Smit V.T., Putter H., Jurgenliemk-Schulz I.M., Jobsen J.J., Lutgens L.C., et al.: “Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial”. Lancet, 2010, 375, 816.

[8] Lum M.M., Belnap T.W., Frandsen J., Brown A.P., Sause W.T., Soisson A.P., et al.: “Survival Analysis of Cancer Patients With FIGO Stage IIIA Endometrial Cancer”. Am. J. Clin. Oncol., 2015, 38, 283.

[9] Brown A.P., Gaffney D.K., Dodson M.K., Soisson A.P., Belnap T.W., Allerman K., et al.: “Survival analysis of endometrial cancer patients with positive lymph nodes”. Int. J. Gynecol. Cancer, 2013, 23, 861.

[19] Klopp A.H., Jhingran A., Ramondetta L, Lu K., Gershenson D.M., Eifel P.J.: “Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation”. Gynecol. Oncol., 2009, 115, 6.

[11] Rose P.G., Cha S.D., Tak W.K., Fitzgerald T., Reale F., Hunter R.E.: “Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma”. Int J. Radiat.Oncol. Biol. Phys., 1992, 24, 229.

[12] Nelson G., Randall M., Sutton G., Moore D., Hurteau J., Look K.: “FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy”. Gynecol. Oncol., 1999, 75, 211.

[13] Schmid S., Hsu I.C., Hu J.M., Sherman A.E., Osann K., Kapp D.S., et al.: “Adjuvant radiation therapy in stage III node-positive uterine cancer”. Gynecol Oncol., 2009, 115, 239.

[14] McMeekin D.S., Lashbrook D., Gold M., Johnson G., Walker J.L., Mannel R.: “Analysis of FIGO Stage IIIc endometrial cancer patients”. Gynecol. Oncol., 2001, 81, 273.

[15] Mundt A.J., Murphy K.T., Rotmensch J., Waggoner S.E., Yamada S.D., Connell P.P.,: “Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma”. Int. J. Radiat. Oncol. Biol. Phys., 2001, 50, 1154.

[16] Pecorelli S.: “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium”. Int. J. Gynaecol. Obstet., 2009, 105, 103.

[17] Zaino R.J.: “FIGO staging of endometrial adenocarcinoma: a critical review and proposal”. Int. J. Gynaecol. Pathol., 2009, 28, 1.

[18] Scully R.E., Bonfiglio, T.A., Kurman, R.J., et al.: “Histological typing of female genital tract tumors: in collaboration with pathologists in 10 countries”. 2nd ed. Heidelberg: Springer-Verlag, 1994.

[19] Therasakvichya S., Kuljarusnont S., Petsuksiri J., Chaopotong P., Achariyapota v., Sichaikul P., et al.: “Clinical outcomes of stage I endometrial carcinoma patients treated with surgery alone: Siriraj Hospital experiences”. J. Gynecol. Oncol., 2016, 27, e48.

[20] Frost J.A., Webster K.E., Bryant A., Morrison J.: “Lymphadenectomy for the management of endometrial cancer”. Cochrane. Database Syst Rev., 2015, 9, CD007585.

[21] Smith D.C., Macdonald O.K., Lee C..M, Gaffney D.K.: “Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis”. Int. J. Gynecol. Cancer, 2008, 18, 255.

[22] Chan J.K., Wu H., Cheung M.K., Shin J.Y., Osann K., Kapp D.S.: “The outcomes of 27,063 women with unstaged endometrioid uterine cancer”. Gynecol Oncol., 2007, 106, 282.

[23] Randall M.E., Filiaci V.L., Muss H., Spirtos N.M., Mannel R.S., Fowler J., et al.: “Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study”. J. Cliin. Oncol., 2006, 24, 36.

[24] Susumu N., Sagae S., Udagawa Y., Niwa K., Kuramoto H., Satoh S, et al.: “Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study”. Gynecol. Oncol., 2008, 108, 226.

[25] Maggi R., Lissoni A., Spina F., Melpignano M., Zola P., Favalli G, et al.: “Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial”. Br. J. Cancer, 2006, 95, 266.

[26] Greven K., Winter K., Underhill K., Fontenesci J., Cooper J., Burke T.: “Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer”. Gynecol. Oncol., 2006, 103, 155.

[27] Morrow C.P., Bundy B.N., Homesley H.D., Creasman W.T., Hornback N.B., Kurman R., et al.: “Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study”. Gynecol. Oncol., 1990, 36, 166.

[28] Hogberg T., Signorelli M., de Oliveira C.F., Fossati R., Lissoni A.A., Sorbe B., et al.: “Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies”. Eur. J. Cancer, 2010, 46, 2422.

[29] Kuoppala T., Maenpaa J., Tomas E., Puistola U., Salmi T., Grenman S., et al.: “Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy”. Gynecol. Oncol., 2008, 110, 190.

[30] Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., Dubeshter B., Burger R.A., et al.: “Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study”. J. Clin. Oncol., 2004, 22, 3902.

[31] Fleming G.F., Filiaci V.L., Bentley R.C., Herzog T., Sorosky J., Vaccarello L., et al.: “Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study”. Ann. Oncol., 2004, 15, 1173.

[32] Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al.: “Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study”. J. Clin. Oncol., 2004, 22, 2159.

[33] Homesley H.D., Filiaci V., Gibbons S.K., Long H.J., Cella D., Spirtos N.M., et al.: “A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study”. Gynecol. Oncol., 2009, 112, 543.

[34] Nakayama K., Nagai Y., Ishikawa M., Aoki Y., Miyazaki K.: “Concomitant postoperative radiation and chemotherapy following surgery was associated with improved overall survival in patients with FIGO stages III and IV endometrial cancer”. Int. J. Clin.Oncol., 2010, 15, 440.

[35] Marchetti C., Pisano C., Mangili G., Lorusso D., Panici P.B., Silvestro G., et al.: “Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: a multicenter retrospective study”. Oncology, 2011, 81, 104.

[36] Secord A.A., Havrilesky L.J., O'Malley D.M., Bae-Jump V., Fleming N.D., Broadwater G., et al.: “A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer”. Gynecol. Oncol., 2009, 114, 442.

[37] Secord A.A., Geller M.A., Broadwater G., Holloway R., Shuler K., Dao N.Y., et al.: “A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer”. Gynecol. Oncol., 2013, 128, 65.

[38] Boothe D., Orton A., Odei B., Stoddard G., Suneja G., Poppe M.M., et al.: “Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival”. Gynecol. Oncol., 2016, 141, 421.

[39] Colombo N., Creutzberg C., Amant F., Bosse T., Gonzalez-Martin A., Ledermann J., et al.: “ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up”. Ann. Oncol., 2016, 27, 16.